Combination of | |
---|---|
Dextromethorphan | Sigma-1 receptor agonist, NMDA receptor antagonist, serotonin–norepinephrine reuptake inhibitor |
Quinidine | Antiarrhythmic agent, CYP2D6 inhibitor |
Clinical data | |
Trade names | Nuedexta |
Other names | AVP-923; DXM/quinidine |
AHFS/Drugs.com | Monograph |
MedlinePlus | a611048 |
License data | |
Routes of administration | By mouth |
ATC code |
|
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | dextromethorphan 11%, quinidine 70-80%. Food has no effect on absorption. |
Metabolism | Liver, extensive. Dextromethorphan is catalyzed by CYP2D6. Quinidine is metabolized by CYP3A4 and competitively inhibits the metabolism of dextromethorphan to increase and prolong plasma concentrations of dextromethorphan |
Elimination half-life | dextromethorphan 13h, quinidine 7h |
Excretion | quinidine 5-20% |
Identifiers | |
CAS Number | |
KEGG |
Dextromethorphan/quinidine, sold under the brand name Nuedexta, is a fixed-dose combination medication for the treatment of pseudobulbar affect (PBA).[2][3] It contains dextromethorphan (DXM) and the class I antiarrhythmic agent quinidine.[2]
Dextromethorphan/quinidine was approved for medical use in the United States in October 2010, and is marketed by Avanir Pharmaceuticals.[4]